NasdaqGS:ABCLLife Sciences
Why AbCellera Biologics (ABCL) Is Back In The Spotlight
Why AbCellera Biologics Stock Is Back In Focus
AbCellera Biologics (ABCL) has drawn fresh attention after announcing an upcoming oral presentation of Phase 2 data for its investigational menopause drug ABCL635 at the International Menopause Society congress.
The treatment targets moderate to severe vasomotor symptoms such as hot flashes, an area with a large patient population and meaningful unmet need, which helps explain why traders are watching the shares ahead of the data update.
The...